{"id":11436,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:36:28","modified_gmt":"2025-10-04T08:36:28","slug":"vliv-hypertermie-kvalitu-zivota-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/cs\/vliv-hypertermie-kvalitu-zivota-qol\/","title":{"rendered":"Vliv hypertermie na kvalitu \u017eivota (QoL): \u00daleva od bolesti, sn\u00ed\u017een\u00ed \u00fanavy a adjuvantn\u00ed imunologick\u00e9 p\u0159\u00ednosy"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Vliv hypertermie na kvalitu \u017eivota (QoL): \u00daleva od bolesti, sn\u00ed\u017een\u00ed \u00fanavy a adjuvantn\u00ed imunologick\u00e9 p\u0159\u00ednosy\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hypertermie, Onkologie, klinick\u00e1 studie f\u00e1ze III, QoL, bolest, E-E-A-T\"\n      \/*... Sch\u00e9ma FAQPage by bylo p\u0159id\u00e1no zvl\u00e1\u0161\u0165 pro sekci \u010casto kladen\u00e9 dotazy *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorita a Odbornost (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autor: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cs\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, a <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cs\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vliv hypertermie na kvalitu \u017eivota (QoL): \u00daleva od bolesti, sn\u00ed\u017een\u00ed \u00fanavy a adjuvantn\u00ed imunologick\u00e9 p\u0159\u00ednosy<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V modern\u00ed onkologii usiluje l\u00e9\u010dba rakoviny o optim\u00e1ln\u00ed rovnov\u00e1hu mezi<a href=\"https:\/\/andromedichyperthermia.com\/cs\/hypertermie-preziti-pacientu\/\"> P\u0159e\u017eit\u00edm (OS\/DFS)<\/a> a <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvalitou \u017divota (QoL).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hypertermie (HT) p\u0159edstavuje jedine\u010dnou adjuvantn\u00ed modalitu, kter\u00e1 prok\u00e1zala v rozs\u00e1hl\u00fdch klinick\u00fdch studi\u00edch ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cs\/hypertermie-studii-faze-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RCT f\u00e1ze III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) zlep\u0161en\u00ed QoL na mnoha \u00farovn\u00edch: kontrola symptom\u016f, celkov\u00fd funk\u010dn\u00ed stav a vynikaj\u00edc\u00ed bezpe\u010dnostn\u00ed profil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Hlavn\u00ed Paliativn\u00ed P\u0159\u00ednos: Kontrola Bolesti (d\u016fkazy \u00farovn\u011b A1 z klinick\u00fdch studi\u00ed F\u00e1ze III)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastatick\u00e1 bolest kost\u00ed zhor\u0161uje QoL. Lokoregion\u00e1ln\u00ed RF hypertermie, kombinovan\u00e1 s Radioterapi\u00ed (RT), poskytuje vynikaj\u00edc\u00ed paliativn\u00ed kontrolu, podle <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">studie F\u00e1ze III publikovan\u00e9 Chi MS a kol<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Ukazatel\/Zlep\u0161en\u00ed Bolesti<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapie<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermie (HT)<\/span><\/span><\/th>\n<th>Vliv na QoL<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00edra Kompletn\u00ed Odpov\u011bdi (CR) po 3 M\u011bs\u00edc\u00edch<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulov\u00e9 sk\u00f3re bolesti)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533% n\u00e1r\u016fst \u0161anc\u00ed na \u00fapln\u00e9 odstran\u011bn\u00ed bolesti.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Doba Trv\u00e1n\u00ed \u00dalevy od Bolesti<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: 55 dn\u016f\/7,9 t\u00fddne<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: Nedosa\u017een ve 24. t\u00fddnu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Doba trv\u00e1n\u00ed \u00falevy se ztrojn\u00e1sobuje, sni\u017euje se z\u00e1vislost na analgetic\u00edch.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V roce <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 publikovali Sahinbas a kolegov\u00e9 studii F\u00e1ze III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pro bolest kostn\u00edch metast\u00e1z, p\u0159ev\u00e1\u017en\u011b z rakoviny prsu a prostaty, s pou\u017eit\u00edm WBHT wIRA hypertermie nav\u00edc k RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Na z\u00e1klad\u011b t\u00e9to studie vykazovala skupina l\u00e9\u010den\u00e1 pouze radioterapi\u00ed (RT) nejintenzivn\u011bj\u0161\u00ed bolest. Studie byla dokon\u010dena po za\u0159azen\u00ed celkem 61 pacient\u016f, 5 let po prvn\u00edm za\u0159azen\u00ed (duben 2016 \u2013 \u00fanor 2021). Nakonec m\u00edra CR ve skupin\u011b RT + WBH uk\u00e1zala nejv\u00fdznamn\u011bj\u0161\u00ed rozd\u00edl oproti samotn\u00e9 RT, a to 47,4 % vs. 5,3 %, v pr\u016fb\u011bhu 2 m\u011bs\u00edc\u016f po l\u00e9\u010db\u011b (hodnota P &lt; 0,05). Doba do \u00fapln\u00e9 \u00falevy od bolesti byla 10 dn\u016f pro RT + WBH, zat\u00edmco ve skupin\u011b RT v monoterapii nebylo dosa\u017eeno kone\u010dn\u00e9ho krit\u00e9ria. Progrese bolesti nebo stabilita onemocn\u011bn\u00ed byly pozorov\u00e1ny u poloviny pacient\u016f ve skupin\u011b RT do 4 t\u00fddn\u016f po l\u00e9\u010db\u011b. Nicm\u00e9n\u011b, toto sk\u00f3re bylo t\u00e9m\u011b\u0159 nulov\u00e9 u pacient\u016f RT + WBHT b\u011bhem dvou m\u011bs\u00edc\u016f po l\u00e9\u010db\u011b.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1v\u011bry:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT prok\u00e1zaly v\u00fdznamn\u00e9 zv\u00fd\u0161en\u00ed \u00falevy od bolesti a krat\u0161\u00ed dobu odpov\u011bdi ve srovn\u00e1n\u00ed se samotnou RT u pacient\u016f s metastatick\u00fdmi kostn\u00edmi l\u00e9zemi.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Ukazatel\/Zlep\u0161en\u00ed Bolesti<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapie<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermie (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vliv na QoL<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00edra Kompletn\u00ed Odpov\u011bdi (CR) po 2 M\u011bs\u00edc\u00edch<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulov\u00e9 sk\u00f3re bolesti)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % n\u00e1r\u016fst<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * \u0161anc\u00ed na \u00fapln\u00e9 odstran\u011bn\u00ed bolesti.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Doba do \u00fapln\u00e9 \u00falevy od bolesti<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">nebyla dosa\u017eena<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dn\u016f<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00fdznamn\u00fd a Rychl\u00fd P\u0159\u00ednos<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Doba Trv\u00e1n\u00ed \u00dalevy od Bolesti\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: 28 dn\u016f\/4 t\u00fddny u poloviny pacient\u016f<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u00e1n: Nedosa\u017een ve 24. t\u00fddnu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Doba trv\u00e1n\u00ed \u00falevy * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">se zvy\u0161uje \u0161estkr\u00e1t<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, sni\u017euje se z\u00e1vislost na analgetic\u00edch.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Zlep\u0161en\u00ed Funk\u010dn\u00edho Stavu a Sn\u00ed\u017een\u00ed \u00danavy<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u0159\u00ednos HT na QoL je p\u0159\u00edmo m\u011b\u0159iteln\u00fd pomoc\u00ed standardizovan\u00fdch dotazn\u00edk\u016f (EORTC QLQ-C30), prokazuj\u00edc\u00ed zlep\u0161en\u00ed celkov\u00e9ho stavu (Fyzick\u00e1 Funkce, \u00danava a \u00dazkost):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00fdznamn\u011b Zlep\u0161en\u00e1 QoL (modulovan\u00e1 RF hypertermie mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomizovan\u00e1 klinick\u00e1 studie Modulovan\u00e9 RF Hypertermie (mEHT) u karcinomu d\u011blo\u017en\u00edho \u010d\u00edpku (LACC) zaznamenala v\u00fdznamn\u00e9 zlep\u0161en\u00ed dlouhodob\u00fdch sk\u00f3re QoL, p\u0159i\u010dem\u017e pacienti hl\u00e1sili lep\u0161\u00ed v\u00fdsledky na \u0161k\u00e1l\u00e1ch Fyzick\u00e9 a Emocion\u00e1ln\u00ed Funkce.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kontrola \u00danavy a Imunomodulace:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Celot\u011blov\u00e1 Hypertermie (WBHT) a HT obecn\u011b pozitivn\u011b ovliv\u0148uj\u00ed chronickou \u00fanavu (CRF) modulac\u00ed proz\u00e1n\u011btliv\u00fdch cytokin\u016f (IL-6, TNF-alfa). HT tak\u00e9 pom\u00e1h\u00e1 udr\u017eovat a zlep\u0161ovat sk\u00f3re na \u0161k\u00e1l\u00e1ch Fyzick\u00e9 a Emocion\u00e1ln\u00ed Funkce v dlouhodob\u00e9m horizontu.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rychl\u00e9 Emocion\u00e1ln\u00ed Zotaven\u00ed (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Po rozs\u00e1hl\u00fdch chirurgick\u00fdch z\u00e1kroc\u00edch, kter\u00e9 zahrnuj\u00ed HT (HIPEC), m\u00e1 emocion\u00e1ln\u00ed QoL tendenci se rychle zlep\u0161ovat, po\u010d\u00ednaje ji\u017e *3 m\u011bs\u00edce po operaci, \u010dasto p\u0159ekra\u010duj\u00edc\u00ed z\u00e1kladn\u00ed \u00farovn\u011b.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Konsolidace Dlouhodob\u00fdch QoL P\u0159\u00ednos\u016f<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Data z re\u00e1ln\u00e9ho sv\u011bta a klinick\u00e9 studie u pokro\u010dil\u00fdch karcinom\u016f potvrzuj\u00ed roli hypertermie ve stabilizaci a zlep\u0161en\u00ed dlouhodob\u00e9 QoL:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurativn\u00ed Vliv po 12 M\u011bs\u00edc\u00edch:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Rozs\u00e1hl\u00e1 anal\u00fdza pacient\u016f l\u00e9\u010den\u00fdch s kurativn\u00edm z\u00e1m\u011brem (RCT + HT) uk\u00e1zala v\u00fdznamn\u00e9 zlep\u0161en\u00ed, udr\u017eovan\u00e9 po *dobu 12 m\u011bs\u00edc\u016f, ve sk\u00f3re v pod\u0161k\u00e1l\u00e1ch QoL hodnot\u00edc\u00edch **Emocion\u00e1ln\u00ed Funkci, Soci\u00e1ln\u00ed Funkci* a *Nespavost (SL)*, ve srovn\u00e1n\u00ed s onkologickou referen\u010dn\u00ed populac\u00ed EORTC.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palijativn\u00ed P\u0159\u00ednosy:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> V paliativn\u00edm kontextu vedlo p\u0159id\u00e1n\u00ed HT ke standardn\u00ed l\u00e9\u010db\u011b ke klinicky relevantn\u00edmu zlep\u0161en\u00ed *Bolesti (PA)* a sn\u00ed\u017een\u00ed *Finan\u010dn\u00edch Pot\u00ed\u017e\u00ed (FI)* *3 m\u011bs\u00edce po l\u00e9\u010db\u011b*, co\u017e p\u0159isp\u011blo k lep\u0161\u00edmu celkov\u00e9mu stavu pacienta.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zlep\u0161en\u00e1 QoL u Pokro\u010dil\u00e9ho Onemocn\u011bn\u00ed (Kolorekt\u00e1ln\u00ed Karcinom):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ve studii hodnot\u00edc\u00ed Vysokofrekven\u010dn\u00ed Hypertermii asistovanou chemoterapi\u00ed u pacient\u016f se st\u0159edn\u00edm a pokro\u010dil\u00fdm stadiem kolorekt\u00e1ln\u00edho karcinomu, skupina, kter\u00e1 obdr\u017eela kombinaci, vyk\u00e1zala v\u00fdznamn\u011b vy\u0161\u0161\u00ed (zlep\u0161en\u00e9) sk\u00f3re QoL po 4 cyklech l\u00e9\u010dby, co\u017e dokazuje, \u017ee HT \u00fa\u010dinn\u011b zlep\u0161uje QoL, krom\u011b terapeutick\u00fdch \u00fa\u010dink\u016f, p\u0159i zachov\u00e1n\u00ed lep\u0161\u00ed bezpe\u010dnosti.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvantn\u00ed Biologick\u00e9 P\u0159\u00ednosy a Vy\u0161\u0161\u00ed Terapeutick\u00fd Index<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maximalizuje letalitu l\u00e9\u010dby bez v\u00fdznamn\u00e9ho zv\u00fd\u0161en\u00ed rizika z\u00e1va\u017en\u00e9 toxicity (Stupe\u0148 3-4), \u010d\u00edm\u017e udr\u017euje vysok\u00fd Terapeutick\u00fd Index:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Validovan\u00e1 Bezpe\u010dnost (klinick\u00e9 studie F\u00e1ze III):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Meta-anal\u00fdzy u karcinomu d\u011blo\u017en\u00edho \u010d\u00edpku prokazuj\u00ed \u017e\u00e1dn\u00fd v\u00fdznamn\u00fd rozd\u00edl v akutn\u00ed nebo pozdn\u00ed toxicit\u011b (RR Toxicita 1.01)[6]. Bezpe\u010dnostn\u00ed profil je udr\u017eov\u00e1n u Rakoviny Kone\u010dn\u00edku[7] a ve studi\u00edch Rakoviny Slinivky B\u0159i\u0161n\u00ed.[8]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ochrana Org\u00e1n\u016f:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> U Rakoviny Kone\u010dn\u00edku zvy\u0161uje p\u0159id\u00e1n\u00ed HT k neoadjuvantn\u00ed chemoradioterapii 5let\u00e9 P\u0159e\u017eit\u00ed Bez Kolostomie (CFS) z 69,0 % na 87,7 %, co\u017e je velk\u00fd funk\u010dn\u00ed p\u0159\u00ednos pro QoL.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abskop\u00e1ln\u00ed Efekt (Vakc\u00edn\u011b Podobn\u00fd):<\/strong> HT spou\u0161t\u00ed imunogenn\u00ed bun\u011b\u010dnou smrt, uvol\u0148uje Proteiny Teplotn\u00edho \u0160oku (HSPs), kter\u00e9 aktivuj\u00ed cytotoxick\u00e9 CD8+ T bu\u0148ky. Toto syst\u00e9mov\u00e9 imunologick\u00e9 primov\u00e1n\u00ed p\u0159isp\u00edv\u00e1 ke kontrole zbytkov\u00e9 nemoci a je z\u00e1sadn\u00edm adjuvantn\u00edm p\u0159\u00ednosem.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1v\u011br: Terapie Zam\u011b\u0159en\u00e1 na Pacienta<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integrace Hypertermie do onkologick\u00e9ho protokolu p\u0159edstavuje pokro\u010dilou, na d\u016fkazech zalo\u017eenou strategii, kter\u00e1 nejen zlep\u0161uje P\u0159e\u017eit\u00ed, ale tak\u00e9 poskytuje robustn\u00ed kontrolu symptom\u016f a udr\u017euje Kvalitu \u017divota. \u00daleva od bolesti, kontrola \u00fanavy a vynikaj\u00edc\u00ed bezpe\u010dnostn\u00ed profil \u010din\u00ed z HT nezbytn\u00fd prvek holistick\u00e9 p\u00e9\u010de o onkologick\u00e9ho pacienta.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zveme v\u00e1s ke konzultaci s na\u0161imi odborn\u00edky, abyste integrovali Hypertermii do va\u0161eho protokolu s c\u00edlem maximalizovat jak \u00fa\u010dinnost, tak Kvalitu \u017divota.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT Z\u00e1ruka:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Tento obsah je zalo\u017een na publikovan\u00fdch datech z randomizovan\u00fdch a prospektivn\u00edch klinick\u00fdch studi\u00ed F\u00e1ze III, vyu\u017e\u00edvaj\u00edc\u00edch standardizovan\u00e9 n\u00e1stroje pro m\u011b\u0159en\u00ed Kvality \u017divota (EORTC QLQ-C30). \u00dapln\u00e9 reference jsou integrov\u00e1ny s p\u0159\u00edm\u00fdmi odkazy na zdrojov\u00e9 publikace.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Reference:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorita a Odbornost (EEAT): Autor: Dr. Veronica Iatan , MD, a Cristian Gologan M.Sc , Andromedichyperthermia Vliv hypertermie na kvalitu \u017eivota (QoL): \u00daleva od bolesti, sn\u00ed\u017een\u00ed \u00fanavy a adjuvantn\u00ed imunologick\u00e9 p\u0159\u00ednosy V modern\u00ed onkologii usiluje l\u00e9\u010dba rakoviny o optim\u00e1ln\u00ed rovnov\u00e1hu mezi P\u0159e\u017eit\u00edm (OS\/DFS) a Kvalitou \u017divota (QoL). Hypertermie (HT) p\u0159edstavuje jedine\u010dnou adjuvantn\u00ed modalitu, kter\u00e1 prok\u00e1zala&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[879,29,111],"tags":[1059,880,881,882,152,1058,755,885,886],"class_list":["post-11436","post","type-post","status-publish","format-standard","hentry","category-studii-clinice-cs","category-uncategorized-cs","category-zpravy","tag-bolest","tag-calitatea-vietii-cs","tag-durere-cs","tag-hipertermie-oncologica-cs","tag-hypertermie","tag-klinicka-studie-faze-iii","tag-onkologie-cs","tag-qol-cs","tag-studii-faza-iii-cs"],"gutentor_comment":44,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/posts\/11436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/comments?post=11436"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/posts\/11436\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/media?parent=11436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/categories?post=11436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/tags?post=11436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}